Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.4152W HIGH $18.43
Volume
192.50 K
Value Traded
3.10 M
Short % Float
11.25%
-3.47%Week
-27.94%1 Month
+25.83%3 Month
+26.22%6 Month
+5.68%5 Year
+5.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
996.01 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
562.94 M
Total Shares
48.03 M
Float Shares
19.64 M
Insiders
59.13%
Institutions
30.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ODTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Odyssey Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Odyssey Therapeutics, Inc.
10Total events
3Upcoming
2Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 5
▲Partnership / LicenseCorporate
Evotec and Odyssey enter AI-enabled R&D collaboration in autoimmune and inflammatory diseases
autoimmune and inflammatory diseasessource ↗
◆Trial InitiationOD-001Trial
Phase 2a combination trial of OD-001 with vedolizumab expected to initiate
ulcerative colitissource ↗
◆IND Enabling CompleteOD-002Preclinical
IND-enabling studies for OD-002 expected to complete
autoimmune diseasessource ↗
Past FDA Catalysts and PDUFA Decisions
How ODTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$208M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 42%
Micro Cap(rank 276 of 655)
Percentile Rank
Odyssey Therapeutics, Inc. faces pipeline headwinds (39/100), with $519M risk-adjusted pipeline value, led by OD-07656 in Ulcerative Colitis (UC) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OD-07656 Small moleculeNCT06850727 | Ulcerative Colitis (UC) | Phase 2 | RECRUITING | 57 | Nov 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ODTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TPG GP A, LLCFormer 10% Owner | Other | 423,111 423,111 held | $0.00 | 05/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ODTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 0.5 % | 7.95 M | 425.00 K |
ODTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ODTX ranks across every disease it competes in
Competitive Position is a premium feature
See how ODTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialODTX News
-ODTX
Sep 16, 2026▲ +5.1%on this news
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23. The event will be accessible via a live webcast and will feature members of the management team discussing the company's innovative approaches to treating autoimmune and inflammatory diseases. Odyssey aims to develop targeted therapies that address unmet medical needs.
Read more →-ODTX
Aug 26, 2026Odyssey Therapeutics to Participate in Upcoming Investor Conferences
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in September 2026. These events include the Cantor Global Healthcare Conference, the Morgan Stanley Global Healthcare Conference, and the H.C. Wainwright Global Investment Conference. The company aims to showcase its innovative approach to treating autoimmune and inflammatory diseases.
Read more →-ODTX
Aug 6, 2026Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Evotec SE has partnered with Odyssey Therapeutics to enhance drug discovery for autoimmune and inflammatory diseases. This collaboration will utilize Evotec's AI-enabled platform and advanced screening capabilities to identify new small molecule drug candidates. The goal is to expedite the development of innovative therapies that address significant unmet medical needs.
Read more →-ODTX
Aug 4, 2026▲ +10.1%on this newsshared move
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics reported its Q2 2026 financial results, highlighting positive proof-of-concept data for OD-001. The company plans to initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab later this year. With $433.1 million in cash, Odyssey is well-positioned to fund operations into 2028. The company also plans to file a clinical trial application for OD-002 by year-end.
Read more →-ODTX
Jun 17, 2026Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics reported positive clinical proof-of-concept data for its oral RIPK2 scaffolding inhibitor, OD-001, in a Phase 2a trial for ulcerative colitis. The company has a strong financial position with $464 million expected to support operations through 2028. Odyssey plans to advance OD-001 into late-stage development and initiate additional trials in the near future.
Read more →-ODTX
May 8, 2026Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
Odyssey Therapeutics has announced the pricing of its upsized initial public offering, selling 15.5 million shares at $18.00 each. The offering, which could raise approximately $304 million, includes a concurrent private placement. Trading is expected to begin on the Nasdaq Capital Market under the ticker 'ODTX' on May 8, 2026.
Read more →-ODTX
Mar 10, 2026Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board
Odyssey Therapeutics has appointed Dr. H. Martin Seidel to its Scientific Advisory Board. Dr. Seidel brings decades of experience in drug discovery and development, having held leadership roles at IFM Therapeutics and Novartis. His expertise is expected to enhance Odyssey's efforts in advancing its clinical programs targeting autoimmune and inflammatory diseases.
Read more →-ODTX
Jan 21, 2026Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
Odyssey Therapeutics has appointed Jolie M. Siegel as Executive Vice President and General Counsel. Siegel will oversee legal, compliance, governance, and risk management functions, playing a key role in supporting the company's growth and strategic opportunities. With over two decades of experience in biotechnology and life sciences, her leadership is expected to enhance Odyssey's capabilities in advancing therapies for autoimmune diseases.
Read more →-ODTX
Nov 11, 2025Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Nonclinical Development
Odyssey Therapeutics has appointed Dennis Dean, Ph.D., as Executive Vice President and Head of Nonclinical Development. Dr. Dean will oversee preclinical research and development, ensuring the progression of drug candidates to clinical trials. His extensive experience in toxicology and pharmacology is expected to enhance the company's capabilities as it advances its portfolio.
Read more →-ODTX
Oct 9, 2025Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to its Board of Directors
Odyssey Therapeutics has appointed Dr. Nia Tatsis to its Board of Directors. Dr. Tatsis, with over 20 years of experience in regulatory affairs, is expected to contribute significantly to the company's clinical development efforts. Odyssey aims to transform care for autoimmune and inflammatory diseases, and Dr. Tatsis's expertise will support their mission to advance their innovative pipeline.
Read more →-ODTX
Sep 10, 2025Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
Odyssey Therapeutics has successfully closed a $213 million Series D financing round, with participation from existing and new investors. The funds will support the advancement of their clinical and preclinical programs targeting autoimmune diseases. The company aims to transform patient care through innovative therapies and has appointed new board members to enhance its governance.
Read more →-ODTX
Jan 8, 2025Odyssey Therapeutics Appoints Jason Haas as Chief Financial Officer
Odyssey Therapeutics has appointed Jason Haas as Chief Financial Officer. With over two decades of experience in financial strategy and operations, Haas will play a key role in advancing the company's financial strategy and growth. His previous roles include CFO at Syros Pharmaceuticals and senior positions in investment banking. The company aims to transform care for autoimmune diseases.
Read more →-ODTX
Oct 28, 2024Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies
Odyssey Therapeutics and Terray Therapeutics have announced a strategic collaboration to discover and develop small molecule therapies targeting transcription factors. This partnership leverages Odyssey's immunology expertise and Terray's advanced AI platform, tNova. The goal is to create innovative treatments for inflammatory diseases, sharing responsibilities and profits equally.
Read more →-ODTX
Oct 27, 2024Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024
Odyssey Therapeutics will present new data on its RIPK2 scaffolding inhibitor, OD-07656, at the ACG Annual Scientific Meeting 2024. The presentation will highlight the compound's anti-inflammatory effects and its potential to work alongside standard therapies for inflammatory bowel disease. CEO Gary D. Glick emphasized the commitment to developing transformative treatments for patients.
Read more →-ODTX
Oct 2, 2024Odyssey Therapeutics Appoints Biopharma Veterans Timothy P. Walbert and Ian F. Smith to its Board of Directors
Odyssey Therapeutics has appointed Timothy P. Walbert and Ian F. Smith to its Board of Directors. Both individuals bring extensive experience in the biopharmaceutical industry, with Walbert having led Horizon Therapeutics and Smith having played a key role at Vertex Pharmaceuticals. Their appointments are expected to enhance Odyssey's strategic growth as it advances its pipeline of precision medicines for inflammatory diseases.
Read more →-ODTX
Sep 27, 2024Odyssey Therapeutics Announces Formation of Scientific Advisory Board
Odyssey Therapeutics has announced the formation of its Scientific Advisory Board, chaired by Dr. Stephen Blacklow. The board consists of leading experts in immunology and therapeutic development, aimed at guiding the company's innovative approaches to treating inflammatory diseases. Odyssey's mission focuses on advancing precision medicines and improving patient outcomes.
Read more →-ODTX
Aug 1, 2024Odyssey Therapeutics Appoints Preeminent Chemist Dr. William Roush as Executive Vice President and Head of Small Molecule Research
Odyssey Therapeutics has appointed Dr. William Roush as Executive Vice President and Head of Small Molecule Research. Dr. Roush brings a wealth of experience in organic and medicinal chemistry, having led numerous drug discovery programs. His role will involve overseeing the preclinical portfolio and accelerating the development of innovative small molecule medicines for autoimmune and inflammatory diseases.
Read more →-ODTX
Apr 4, 2024Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery
Odyssey Therapeutics has announced a strategic collaboration with Janssen Pharmaceutica to enhance the discovery and optimization of small molecule medicines. This partnership will leverage artificial intelligence and machine learning to address challenging therapeutic targets. Odyssey will receive upfront payments and potential royalties as they work together on this initiative.
Read more →-ODTX
Dec 4, 2023Odyssey Therapeutics Announces $101 Million Series C Financing
Odyssey Therapeutics has successfully closed a $101 million Series C financing round, led by Ascenta Capital, with participation from various investors. This funding will facilitate the advancement of multiple clinical programs and support ongoing discovery efforts. The company aims to bring transformative immunology and oncology medicines to patients, with several candidates expected to enter clinical trials within the next year.
Read more →-ODTX
Nov 9, 2023Odyssey Therapeutics to Present Data for Three Immunology Programs at American College of Rheumatology Convergence 2023
Odyssey Therapeutics will present data on three immunology programs at the ACR Convergence 2023. The presentations will include novel therapeutic approaches targeting RIPK2, IRAK4, and TNFR2, which are crucial for treating underserved inflammatory and autoimmune diseases. This marks the first public disclosure of these promising therapies aimed at improving patient outcomes.
Read more →About Odyssey Therapeutics, Inc.
Headquarters51 SLEEPER STREET, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE PLUS
Trade the next ODTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime